The role of statins in inflammatory vasculitides

References

• Ridker, P. M., C. P. Cannon, D. Morrow, et al. (2005). C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352: 20–28
   PubMed Web of Science ®Google Scholar
• Ridker, P. M., E. Danielson, F. A. Fonseca, et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359: 2195–2207
   PubMed Web of Science ®Google Scholar
• Ridker, P. M., N. Rifai, M. A. Pfeffer, et al. (1998). Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 98: 839–844
   PubMed Web of Science ®Google Scholar
• Morrow, D. A., J. A. de Lemos, M. S. Sabatine, et al. (2006). Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 114: 281–288
   PubMed Web of Science ®Google Scholar
• Nissen, S. E., E. M. Tuzcu, P. Schoenhagen, et al. (2005). Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352: 29–38
   PubMed Web of Science ®Google Scholar
• Collins, F. S. (2011). Mining for therapeutic gold. Nat. Rev. Drug Discov. 10: 397
   PubMed Web of Science ®Google Scholar
• Greenwood, J., L. Steinman, and S. S. Zamvil. (2006). Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6: 358–370
   PubMed Web of Science ®Google Scholar
• Kim, Y. C., K. K. Kim, and E. M. Shevach. (2010). Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology. 130: 484–493
   Google Scholar
• Tang, T. T., Y. Song, Y. J. Ding, et al. (2011). Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J. Lipid Res. 52: 1023–1032
   PubMed Web of Science ®Google Scholar
• Meyer-Ter-Vehn, T., B. Katzenberger, H. Han, et al. (2008). Lovastatin inhibits TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest. Ophthalmol. Vis. Sci. 49: 3955–3960
   PubMed Web of Science ®Google Scholar
• Porter, K. E., N. A. Turner, D. J. O'Regan, and S. G. Ball. (2004). Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc. Res. 64: 507–515
   PubMed Web of Science ®Google Scholar
• Schmidt-Lucke, C., S. Fichtlscherer, L. Rossig, et al. (2010). Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 211: 249–254
   PubMed Web of Science ®Google Scholar
• de Jongh, S., M. R. Lilien, J. op't Roodt, et al. (2002). Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 40: 2117–2121
   PubMed Web of Science ®Google Scholar
• Kosmidou, I., J. P. Moore, M. Weber, and C. D. Searles. (2007). Statin treatment and 3′ polyadenylation of eNOS mRNA. Arterioscler. Thromb. Vac. Biol. 27: 2642–2649
   Google Scholar
• Su, Y., Y. Xu, Y. M. Sun, et al. (2010). Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. J. Cardiovasc. Pharmacol. 55: 21–25
   PubMed Web of Science ®Google Scholar
• Wassmann, S., U. Laufs, K. Muller, et al. (2002). Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vac. Biol. 22: 300–305
   PubMed Web of Science ®Google Scholar
• Guzik, T. J., J. Sadowski, B. Guzik, et al. (2006). Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler. Thromb. Vac. Biol. 26: 333–339
   PubMed Web of Science ®Google Scholar
• Delbosc, S., M. Morena, F. Djouad, et al. (2002). Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J. Cardiovasc. Pharmacol. 40: 611–617
   PubMed Web of Science ®Google Scholar
• Yurdakul, S., V. Hamuryudan, and H. Yazici. (2011). Behcet Syndrome. Philadelphia, PA: Elsevier
   Google Scholar
• Inanc, M. T., N. Kalay, T. Heyit, et al. (2010). Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Behcet's disease. Echocardiography. 27: 997–1003
   PubMed Web of Science ®Google Scholar
• McCarey, D. W., I. B. McInnes, R. Madhok, et al. (2004). Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 363: 2015–2021
   PubMed Web of Science ®Google Scholar
• Pereira, M. C., P. R. Cardoso, L. F. Da Rocha, Jret al. (2014). Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis. Inflamm. Res. 63: 309–315
   PubMedGoogle Scholar
• Blaschke, S., V. Viereck, G. Schwarz, et al. (2009). Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand. J. Rheumatol. 38: 235–239
   PubMed Web of Science ®Google Scholar
• Yokota, K., T. Miyazaki, M. Hirano, et al. (2006). Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 33: 463–471
   PubMed Web of Science ®Google Scholar
• Tang, T. T., Y. Song, Y. J. Ding, et al. (2011). Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J. Lipid Res. 52: 1023–1032
   PubMed Web of Science ®Google Scholar
• Chalubinski, M., and M. Broncel. (2010). Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders. Med. Sci. Monit. 16: RA245–RA251
   Google Scholar
• Lv, S., Y. Liu, Z. Zou, et al. (2014). The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin. Exp. Rheumatol. 33: 69–76
   Google Scholar
• Kawasaki, T., F. Kosaki, S. Okawa, et al. (1974). A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 54: 271–276
   PubMed Web of Science ®Google Scholar
• Taubert, K. A., A. H. Rowley, and S. T. Shulman. (1994). Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr. Infect. Dis. J. 13: 704–708
   PubMed Web of Science ®Google Scholar
• Franco, A., C. Shimizu, A. H. Tremoulet, and J. C. Burns. (2010). Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity. 43: 317–324
   PubMed Web of Science ®Google Scholar
• Shimizu, C., T. Matsubara, Y. Onouchi, et al. (2010). Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. J. Hum. Genet. 55: 779–784
   PubMed Web of Science ®Google Scholar
• Shimizu, C., S. Jain, S. Davila, et al. (2011). Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ. Cardiovasc. Genet. 4: 16–25
   PubMed Web of Science ®Google Scholar
• Sato, Y. Z., D. P. Molkara, L. B. Daniels, et al. (2013). Cardiovascular biomarkers in acute Kawasaki disease. Int. J. Cardiol. 164: 58–63
   Google Scholar
• Shimizu, C., T. Oharaseki, K. Takahashi, et al. (2013). The role of TGF-beta and myofibroblasts in the arteritis of Kawasaki disease. Hum. Pathol. 44: 189–198
   PubMed Web of Science ®Google Scholar
• Kato, H., T. Sugimura, T. Akagi, et al. (1996). Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 94: 1379–1385
   PubMed Web of Science ®Google Scholar
• Gordon, J. B., A. M. Kahn, and J. C. Burns. (2009). When children with kawasaki disease grow up myocardial and vascular complications in adulthood. J. Am. Coll. Cardiol. 54: 1911–1920
   PubMed Web of Science ®Google Scholar
• McCrindle, B. W. (2009). Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation. 120: 6–8
   PubMed Web of Science ®Google Scholar
• Gavin, P. J., S. E. Crawford, S. T. Shulman, et al. (2003). Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler. Thromb. Vac. Biol. 23: 576–581
   PubMed Web of Science ®Google Scholar
• Sakata, K., K. Hamaoka, S. Ozawa, et al. (2010). Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease. Circ. J. 74: 1670–1675
   Google Scholar
• Lau, A. C., T. T. Duong, S. Ito, et al. (2009). Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin. Exp. Immunol. 157: 300–309
   PubMed Web of Science ®Google Scholar
• Mahajan, N., and V. Dhawan. (2010). Inhibition of C-reactive protein induced expression of matrix metalloproteinases by atorvastatin in THP-1 cells. Mol. Cell. Biochem. 338: 77–86
   Google Scholar
• Izidoro-Toledo, T. C., D. A. Guimaraes, V. A. Belo, et al. (2011). Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn. Schmiedebergs Arch. Pharmacol. 383: 547–554
   PubMed Web of Science ®Google Scholar
• Blankier, S., B. W. McCrindle, S. Ito, and R. S. Yeung. (2011). The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clin. Exp. Immunol. 164: 193–201
   PubMed Web of Science ®Google Scholar
• Mausner-Fainberg, K., G. Luboshits, A. Mor, et al. (2008). The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. 197: 829–839
   PubMed Web of Science ®Google Scholar
• Mira, E., B. Leon, D. F. Barber, et al. (2008). Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J. Immunol. 181: 3524–3534
   PubMed Web of Science ®Google Scholar
• Franco, A., R. Touma, Y. Song, et al. (2014). Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity. 47: 95–104
   PubMed Web of Science ®Google Scholar
• Burns, J. C., Y. Song, M. Bujold, et al. (2013). Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin. Exp. Immunol. 174: 337–344
   PubMedGoogle Scholar
• Chow, S. C. (2009). Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch. Immunol. Ther. Exp. (Warsz). 57: 243–251
   PubMed Web of Science ®Google Scholar
• Shimizu, C., S. Jain, S. Davila, et al. (2011). Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ. Cardiovasc. Genet. 4: 16–25
   PubMed Web of Science ®Google Scholar
• Zhang, X., J. Jin, X. Peng, et al. (2008). Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J. Immunol. 180: 6988–6996
   PubMed Web of Science ®Google Scholar
• Porter, K. E., N. A. Turner, D. J. O'Regan, et al. (2004). Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc. Res. 61: 745–755
   PubMed Web of Science ®Google Scholar
• Benton, J. A., H. B. Kern, L. A. Leinwand, et al. (2009). Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression. Arterioscler. Thromb. Vac. Biol. 29: 1950–1957
   Google Scholar
• Turner, N. A., P. K. Aley, K. T. Hall, et al. (2007). Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J. Mol. Cell. Cardiol. 43: 168–176
   PubMed Web of Science ®Google Scholar
• Suda, K., N. Tahara, A. Honda, et al. (2015). Statin reduces persistent coronary arterial inflammation evaluated by serial (18)fluorodeoxyglucose positron emission tomography imaging long after Kawasaki disease. Int. J. Cardiol. 179: 61–62
   Google Scholar
• Duan, C., Z. D. Du, Y. Wang, and L. Q. Jia. (2014). Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease. World J. Pediatr. 10: 232–237
   Google Scholar
• Gandelman, K., P. Glue, R. Laskey, et al. (2011). An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr. Cardiol. 32: 433–441
   PubMed Web of Science ®Google Scholar
• Canas, J. A., J. L. Ross, M. V. Taboada, et al. (2014). A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes. Pediatr. Diabetes. 16: 79–89
   Google Scholar
• Schweitzer, M., B. Mitmaker, D. Obrand, et al. (2010). Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms. Vasc. Endovasc. Surg. 44: 116–122
   PubMed Web of Science ®Google Scholar
• Avis, H. J., M. N. Vissers, E. A. Stein, et al. (2007). A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vac. Biol. 27: 1803–1810
   PubMed Web of Science ®Google Scholar
• Krmar, R. T., J. R. Ferraris, J. A. Ramirez, et al. (2002). Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr. Nephrol. 17: 540–543
   Google Scholar